Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

A Stellar Start to 2021 for Lucid Group

It’s been a stellar start to 2021 for Lucid Group, which has welcomed 38 new starters into the company since the beginning of the year. These include 15 Client Services...

Day in a #LucidLife – Meet Philippa

Ever wondered what a #LucidLife looks like?Philippa McClure, Senior Account Director, takes us through her day. We have a number of roles in client services, just like Philippa's.So, if you like what...

My Journey into Medical Writing #LucidLife

In NetworkPharma’s latest career guide for wannabe medical writers, Jane Juif, Medical Writer, discusses her unconventional journey into the world of medical communications and medical writing.My journey into Med Comms...

LUCID GROUP PARTNERS WITH NEW INVESTOR ICG

Lucid Group has secured a new investment from Intermediate Capital Group (ICG) to support its continued ambition to build a global business that delivers life transforming value for everyone.Founded in...

IWD2021: #ChooseToChallenge Interview with Dennis O’Brien, Lucid Group CEO

Hey Dennis, what does this year’s IWD slogan, #ChooseToChallenge mean to you?I love it. It’s inspirational and action-oriented. It’s clear we need to change many things in our society, inequality...

Rare Disease Day in a COVID-19 environment

For many people and families living with a rare disease, their journey can be very complex. At times, that journey can even be scary, frustrating and confusing. However, when your...

We Celebrate Your Whole Selves: That’s What Makes The Magic

People are at the heart of who we are. Our aim is to transform the lives of those we touch without prejudice or discrimination. At Lucid, the magic we create...

Lucid Group: A Community of Purpose

In this month’s Pharmaceutical Marketing Europe, Lucid Group’s Chief People Officer, Angela Young, discusses the importance of bringing the company’s purpose to life so that its people feel connected to...

A magic milestone: Katherine’s 10-year workiversary

Katherine Duxbury recently celebrated the momentous and magical milestone of 10 years with Lucid Group – congratulations! Surprise virtual celebrations have been had and, while they were no replacement for...

Lucid Group – Let’s Start Talking

We can all help to transform the lives of those we touch by taking the time to talk and listen to one another. The power of conversation, sharing thoughts, worries...